The U.S. Induced Pluripotent Stem Cell (iPSC) market size is expected to reach USD 1,372.22 Million by 2032, exhibiting a CAGR of 9.6% during the forecast period.
The U.S. Induced Pluripotent Stem Cell (iPSC) Market is rapidly expanding, driven by advancements in stem cell research and growing applications in drug discovery, disease modeling, and regenerative medicine. iPSCs, created by reprogramming adult somatic cells to a pluripotent state, can differentiate into any type of cell, making them a valuable resource for various medical and research applications. The market has gained significant momentum in recent years due to ongoing research in regenerative therapies, disease modeling, and personalized medicine.
Key Trends in the Market
- Use of iPSCs in Drug Discovery and Toxicity Testing:
- iPSCs are increasingly being utilized in drug discovery to create models for testing drug efficacy and safety. These models offer a more accurate representation of human biology compared to traditional cell lines, enabling better predictions of drug responses and reducing the risk of adverse effects in clinical trials.
- Clinical Applications and Cell Therapy:
- The use of iPSCs in clinical applications, such as regenerative therapies for damaged tissues and organs, is expanding. Clinical trials involving iPSC-based therapies are underway, focusing on conditions such as retinal degeneration, heart disease, and bone regeneration.
- Partnerships and Collaborations:
- Many biotechnology and pharmaceutical companies are entering into partnerships with academic institutions and research organizations to explore the potential of iPSCs in drug development, regenerative medicine, and disease modeling. These collaborations are accelerating research and providing new opportunities for commercialization.
Download Free Sample PDF Copy of the Report:
Some of the major players operating in the U.S. market include:
- Applied StemCell
- Astellas Pharma Inc.
- Catalent, Inc
- Evotec
- Fate Therapeutics
- FUJIFILM Holdings Corporation (Cellular Dynamics)
- REPROCELL Inc.
- Takara Bio Inc.
Research Scope
Research in the U.S. iPSC Market focuses on several key areas:
- iPSCs in Regenerative Medicine:
- Researchers are investigating how iPSCs can be used to generate functional tissues and organs for transplantation. Studies focus on overcoming challenges like tissue rejection and immune response to make iPSC-based therapies viable for clinical use.
- Disease Modeling:
- iPSCs are being used to create patient-specific disease models, which can be used to study the pathophysiology of diseases, discover new therapeutic targets, and test drug candidates. There is particular focus on neurological diseases, cardiovascular diseases, and cancer.
- Clinical Trials and Therapeutic Applications:
- A growing number of clinical trials are investigating the use of iPSC-based therapies for various medical conditions, including genetic disorders, cardiovascular diseases, diabetes, and autoimmune diseases.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:
The research report categorizes the market into various segments and sub-segments. The primary segments covered in the study include type, application, end use and region. The splitting of the market into various groups enables businesses to understand market preferences and trends better. Also, stakeholders can develop products/services that align with the diverse needs of consumers in the industry. Besides, the research study includes a thorough examination of all the major sub-segments in the market.
U.S. iPSC, Derived Cell Outlook (Revenue – USD Million, 2019 – 2032)
- Hepatocytes
- Fibroblasts
- Neural Cells
- Excitatory Neurons
- Inhibitory Neurons
- Amniotic Cells
- Cardiomyocytes
- Others
U.S. iPSC, Workflow Outlook (Revenue – USD Million, 2019 – 2032)
- Reprogramming
- Cell Culture
- Cell Characterization / Analysis
- Engineering
- Others
U.S. iPSC, Application Outlook (Revenue – USD Million, 2019 – 2032)
- Manufacturing
- Academic Research
- Drug Development & Discovery
- Toxicity Screening
- Regenerative Medicine
Recent Developments
- In September 2019, Fate Therapeutics, Inc. announced the launch of its current Good Manufacturing Process (cGMP) compliant manufacturing facility for clinical production of natural killer (NK) cell and chimeric antigen receptor (CAR) T-cell product candidates. The facility is located in San Diego, California. It is specifically designed for the manufacture of off-the-shelf, allogeneic cell products, using clonal master induced pluripotent stem cell (iPSC) lines as a starting cell source.
- In November 2019, Takara Bio USA, Inc. (TBUSA) has disclosed that Takara Bio Inc., its parent firm, has released the globe’s first commercially accessible small intestine epithelial cells generated from human induced pluripotent stem cells.
The U.S. Induced Pluripotent Stem Cell (iPSC) Market is poised for rapid growth, driven by advancements in stem cell research, disease modeling, regenerative medicine, and personalized therapies. With continued technological advancements, funding, and collaborations between industry and academia, iPSCs hold the potential to revolutionize medicine, particularly in areas such as drug discovery, regenerative therapies, and gene editing. While challenges such as high development costs and regulatory hurdles remain, the future of the iPSC market looks promising as researchers continue to unlock the therapeutic potential of this groundbreaking technology.